Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

The effect of hyperbaric oxygen therapy on myocardial function in post-COVID-19 syndrome patients: a randomized controlled trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      COVID-19*/therapy ; Hyperbaric Oxygenation* ; Cardiovascular Diseases*; Humans ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2
    • Abstract:
      Post-COVID-19 condition refers to a range of persisting physical, neurocognitive, and neuropsychological symptoms following SARS-CoV-2 infection. Recent evidence revealed that post-COVID-19 syndrome patients may suffer from cardiac dysfunction and are at increased risk for a broad range of cardiovascular disorders. This randomized, sham-control, double-blind trial evaluated the effect of hyperbaric oxygen therapy (HBOT) on the cardiac function of post-COVID-19 patients with ongoing symptoms for at least three months after confirmed infection. Sixty patients were randomized to receive 40 daily HBOT or sham sessions. They underwent echocardiography at baseline and 1-3 weeks after the last protocol session. Twenty-nine (48.3%) patients had reduced global longitudinal strain (GLS) at baseline. Of them, 13 (43.3%) and 16 (53.3%) were allocated to the sham and HBOT groups, respectively. Compared to the sham group, GLS significantly increased following HBOT (- 17.8 ± 1.1 to - 20.2 ± 1.0, p = 0.0001), with a significant group-by-time interaction (p = 0.041). In conclusion, post-COVID-19 syndrome patients despite normal EF often have subclinical left ventricular dysfunction that is characterized by mildly reduced GLS. HBOT promotes left ventricular systolic function recovery in patients suffering from post COVID-19 condition. Further studies are needed to optimize patient selection and evaluate long-term outcomes.This study was registered with ClinicalTrials.gov, number NCT04647656 on 01/12/2020.
      (© 2023. The Author(s).)
    • References:
      PLoS One. 2013 Nov 15;8(11):e79995. (PMID: 24260334)
      JAMA Cardiol. 2020 Nov 01;5(11):1265-1273. (PMID: 32730619)
      PLoS One. 2015 May 26;10(5):e0127012. (PMID: 26010952)
      J Clin Med. 2020 Dec 17;9(12):. (PMID: 33348719)
      Clin Res Cardiol. 2021 Jul;110(7):1063-1072. (PMID: 33481096)
      Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70. (PMID: 25712077)
      Int J Gen Med. 2021 Aug 29;14:4977-4985. (PMID: 34511982)
      Echocardiography. 2021 Oct;38(10):1722-1730. (PMID: 34555203)
      J Am Soc Echocardiogr. 2004 Oct;17(10):1021-9. (PMID: 15452466)
      Sci Rep. 2022 Jul 12;12(1):11252. (PMID: 35821512)
      J Am Coll Cardiol. 2017 Feb 28;69(8):1043-1056. (PMID: 28231932)
      Cureus. 2022 Feb 3;14(2):e21879. (PMID: 35265414)
      Nat Rev Cardiol. 2020 Sep;17(9):543-558. (PMID: 32690910)
      JAMA Cardiol. 2021 Jan 1;6(1):116-118. (PMID: 32915194)
      J Am Soc Echocardiogr. 2021 May;34(5):562-566. (PMID: 33539950)
      J Am Soc Echocardiogr. 2019 Aug;32(8):947-957. (PMID: 31043359)
      Expert Rev Neurother. 2014 Mar;14(3):233-6. (PMID: 24471697)
      Clin Nutr ESPEN. 2021 Dec;46:510-518. (PMID: 34857243)
      Front Hum Neurosci. 2017 Oct 19;11:508. (PMID: 29097988)
      PLoS One. 2013;8(1):e53716. (PMID: 23335971)
      Aging (Albany NY). 2020 Jun 26;12(13):13740-13761. (PMID: 32589613)
      J Pers Med. 2022 Jan 04;12(1):. (PMID: 35055360)
      Int J Cardiovasc Imaging. 2020 May;36(5):833-840. (PMID: 31953651)
      Acta Pharmacol Sin. 2021 Oct;42(10):1567-1574. (PMID: 33510459)
      Nature. 2021 Jun;594(7862):259-264. (PMID: 33887749)
      Rev Med Virol. 2022 Jul;32(4):e2315. (PMID: 34888989)
      Clin Microbiol Infect. 2021 Sep;27(9):1250-1261. (PMID: 34171458)
      Biomolecules. 2021 Oct 15;11(10):. (PMID: 34680155)
      Clin Med (Lond). 2021 Nov;21(6):e629-e632. (PMID: 34862223)
      Healthcare (Basel). 2020 Dec 11;8(4):. (PMID: 33322316)
      Life Sci. 2020 Aug 1;254:117788. (PMID: 32475810)
      J Am Soc Echocardiogr. 2021 Feb;34(2):193-195. (PMID: 33243582)
      Int J Cardiol. 2018 May 15;259:116-121. (PMID: 29579586)
      Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1321-1360. (PMID: 27422899)
      Int J Cardiol Heart Vasc. 2021 Feb;32:100719. (PMID: 33521240)
      Clin Rev Allergy Immunol. 2023 Feb;64(1):66-74. (PMID: 33609255)
      Brain Sci. 2021 Nov 02;11(11):. (PMID: 34827455)
      Biomolecules. 2020 Jun 25;10(6):. (PMID: 32630465)
      Int J Cardiovasc Imaging. 2018 May;34(5):787-792. (PMID: 29181826)
      Front Psychol. 2018 Dec 17;9:2495. (PMID: 30618929)
    • Molecular Sequence:
      ClinicalTrials.gov NCT04647656
    • Publication Date:
      Date Created: 20230610 Date Completed: 20230612 Latest Revision: 20231121
    • Publication Date:
      20250114
    • Accession Number:
      PMC10257166
    • Accession Number:
      10.1038/s41598-023-36570-x
    • Accession Number:
      37301934